Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Tecnofarma International under which Cipher has granted Tecnofarma the exclusive right to market and distribute CIP-TRAMADOL ER in Latin America.
Subscribe to our email newsletter
Under the terms of the agreement, Cipher will receive an upfront payment and is eligible for additional milestones based upon regulatory approval in Brazil and Mexico.
CIP-TRAMADOL ER is a patent-protected, extended-release formulation of tramadol, used for the treatment of moderate to moderately severe chronic pain in adults.
The product received approval from the US Food and Drug Administration in 2010.
Cipher Pharmaceuticals president and CEO Larry Andrews said, "Tecnofarma is a significant player in the region with deep experience in pain management, which positions them well to introduce our extended-release tramadol product in key Latin American markets."
Cipher will supply the product to Tecnofarma and the product manufacturing will be fulfilled by Galephar Pharmaceutical Research.